News

In a recent study entitled “Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter” published in the online issue of Nature, the authors determined the structure of an ABC transporter protein with a sub nanometer resolution for the first time. The new findings has implications in…

Proteostasis Therapeutics, a company developing novel therapeutics for Cystic Fibrosis and other diseases to address defects in protein folding, trafficking and clearance, and Astellas Pharma Inc. (“Astellas”), a company dedicated to improving people’s health by providing innovative and reliable pharmaceuticals, announced a worldwide joint collaboration to research and…

Massachusetts-based Vertex Pharmaceuticals, Inc. announced yesterday that they have filed for a New Drug Application (NDA) with the US Food and Drug Administration, and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for their pipeline combination lumacaftor–ivacaftor drug, indicated for the…

A recent study entitled “Stochastic Tracking of Infection in a CF Lung” presents a new algorithm that improves recorded imaging results for examining the lungs of Cystic Fibrosis patients by providing information at a microscopic level of the infection site. This study was published on PlosOne…

Developmental stage biopharmaceutical company Parion Sciences recently announced that the National Institutes of Health‘s grants over the next 5 years in support of pulmonary research programs using their novel pipeline treatments will reach a total of about $15.6 million. These grants have gone to the University of North Carolina,…

Australian specialist pharmaceutical company Pharmaxis has just announced it has successfully enrolled the first participant in an international Phase 3 clinical trial designed to evaluate their lead pipeline product for cystic fibrosis, Bronchitol® (mannitol). Pharmaxis continues to develop novel treatments for chronic respiratory disorders, such as asthma, pulmonary…

A new study on the impact of Cystic Fibrosis carrier status in in vitro fertilization (IVF) procedures and outcomes, entitled “Female cystic fibrosis mutation carriers and assisted reproductive technology: Does carrier status affect reproductive outcomes?“ was recently announced by Celmatix, a New York City-based company…

Santa Fe, New Mexico based startup Avisa Pharma Inc. is a clinical stage company established in 2010 to develop and commercialize a new technology invented by Dr. Graham Timmins, Avisa’s Co-founder/Chief Science Officer and a University of New Mexico College of Pharmacy Associate Professor, who was assisted by colleagues from UNM’s School…

Drug discovery company Proteostasis Therapeutics has completed the recruiting process for its Inaugural Cystic Fibrosis Clinical Advisory Board, a new board appointed by the company to act as a strategic resource responsible for the selection of upcoming studies of its compounds for treating cystic fibrosis. The company is dedicated…

A new study on Staphylococcus aureus infection and cystic fibrosis (CF) entitled “Counteracting suppression of CFTR and voltage-gated K+ channels by a bacterial pathogenic factor with the natural product tannic acid“ was published on eLife by Yajamana Ramu, part of Dr. Zhe Lu’s group…